Jeanette Bachir
Swissmedic(CH)
Publications by Year
Research Areas
Sarcoma Diagnosis and Treatment, Glioma Diagnosis and Treatment, Pancreatic and Hepatic Oncology Research, Renal Transplantation Outcomes and Treatments, Iron Metabolism and Disorders
Most-Cited Works
- → Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study)(2017)93 cited
- → Trials in Progress: A Two-Cohort, Open-Label, Single-Arm Study of Emapalumab, an Anti-Interferon Gamma (IFNγ) Monoclonal Antibody, in Patients with Macrophage Activation Syndrome (MAS) in Rheumatic Diseases(2021)5 cited
- → BERNIE: Open-label, randomized, phase II study of bevacizumab plus chemotherapy in pediatric metastatic rhabdomyosarcoma (RMS) and non-rhabdomyosarcoma soft tissue sarcoma (NRSTS).(2016)5 cited
- → Integrated analysis of long‐term growth and bone development in pediatric and adolescent patients receiving bevacizumab(2018)5 cited
- → Role of radiotherapy to primary/metastatic sites in pediatric patients with metastatic rhabdomyosarcoma in the BERNIE study.(2017)4 cited
- → PEDIATRICS CLINICAL RESEARCH(2013)1 cited
- → Long-term growth and development in 268 bevacizumab (BEV)-treated and 135 control pediatric/adolescent patients (pts): An integrated analysis.(2017)
- HERBY: A PHASE II COMPARATIVE STUDY OF BEVACIZUMAB-BASED THERAPY IN CHILDREN WITH HIGH-GRADE GLIOMA(2013)
- → Trends in pivotal clinical trial design and biomarker use: a retrospective analysis of oncology drug approval in Switzerland from 2001 to 2020(2025)
- → The HERBY study: A phase II open label, randomized, multicenter, comparative study of bevacizumab (Bv)-based therapy in pediatric patients with newly diagnosed supratentorial high-grade glioma (HGG).(2012)